Vipidia tabs 25mg #28

User manual for Vipidia

Reed more and buy Vipidia here

Alogliptin belongs to the group of fundamentally new substances used to treat type 2 diabetes mellitus, which is called incretinomimetiki. Glycagon-like polypeptide and glucose-dependent insulinotropic polypeptide are among the incretins. In response to eating, they begin to stimulate insulin synthesis.
There are 2 groups of incretin mimetics:
    substances with a similar action with incretin (liraglutide, exenatide, lixisenatide);
    substances that prolong the action of physiologically synthesized incretins by reducing the production of a specific enzyme, dipeptidyl peptidase-4, which destroys the incretins. These include: sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin.
          Alogliptin has a strong and highly selective inhibitory effect on the specific enzyme dipeptidyl peptidase-4. Its selectivity for this enzyme is many times greater than the effect on other enzymes of the related type. Dipeptidyl peptidase-4 is the main enzyme that promotes the rapid destruction of hormones from the family of incretins, which are represented by a glucagon-like peptide and glucose-dependent insulinotropic polypeptide. They are formed in the intestines and when eating stimulate insulin synthesis in the pancreas.
The glucagon-like peptide reduces the formation of glucagon and reduces the amount of glucose produced by the liver. Therefore, with increasing incretin content, alogliptin stimulates an increase in glucose-dependent insulin production and decreases glucagon synthesis with an increase in blood glucose. Both of these effects in the production of insulin and glucagon lead to a decrease in the formation and content of glycosylated hemoglobin in patients with diabetes-type insulin-dependent. And also, while there is a normalization of glucose in the blood on an empty stomach and after a meal.

Release form and composition

Vipidia is available in the form of tablets in two dosages. Manufacturer of the medicinal product: Takeda Ireland Limited (Ireland).
1 tablet of the drug contains:
    Alogliptin benzoate - 12.5 or 25 mg;
    various excipients.
The tablets with the amount of the active substance 12.5 mg are yellow in color, and the tablets 25 mg are red, on one side of both dosages they have inscriptions indicating the manufacturer and amount of the substance. Vipidia is subject to prescription only when prescribing a doctor.

Indications for use

Vipidia is an oral hypoglycemic medication. It is indicated for the treatment of diabetes mellitus type II as a means of improving the control of blood glucose levels in the absence of dietary therapy and exercise. The drug is suitable for treatment in the form of monotherapy, combined with other tablets and glucose-lowering drugs with insulin.

Contraindications for Vipidia

    hypersensitivity to alogliptin, excipients or other drugs belonging to this group in history;
    type I diabetes;
    ketoacidosis on the background of diabetes mellitus;
    severe heart failure;
    severe liver disease, accompanied by functional insufficiency;
    severe renal pathology, accompanied by functional insufficiency;
    pregnancy;
    lactation period;
    age up to 18.
With caution, the drug is prescribed to persons with pancreatitis in history, moderate severity of kidney failure, as well as when combined with other hypoglycemic agents.

Mode of application

The drug is used inside. The average therapeutic dose is 25 mg, taken once, regardless of the meal. The pill is taken whole, washed down with water.
Appointment Vipidia possible:
    as monotherapy for diabetes;
    in the complex treatment of a disease, as a component when taking metformin, thiazolidinedione, sulfonylurea or insulin derivatives;
    as part of the simultaneous treatment of three antidiabetic drugs based on metformin, thiazolidinedione or insulin.
If the dose of Vipidia was missed, it is necessary to take it as soon as possible. But taking a double dose in one day is contraindicated.
When using Vipidia simultaneously with metformin or thiazolidinedione, the dosage of drugs is left unchanged. Dose adjustment is necessary in the case of prescribing a drug with a group of sulfonylurea derivatives or insulin to reduce the likelihood of hypoglycemia. For the same reason, caution is required when prescribing three-component therapy with metformin and thiazolidinedione. If signs of hypoglycemia appear, a reduction in the dosage of metformin or thiazolidinedione is recommended. No studies have been conducted regarding the effect produced and safety when taking alogliptin with metformin and sulfonylurea derivatives.

Side effects of Vipidia

    nervous system: frequent headache is possible;
    digestive tract: pain in the abdomen, throwing the contents of the stomach into the esophagus, acute pancreatitis;
    hepatobiliary system: impaired hepatic function;
    skin and subcutaneous tissue: itching, rashes, various erythroderma, including Stevens-Johnson syndrome, angioedema, urticaria;
    infections and helminthic invasions: infection of the respiratory system, inflammation of the nasal and pharyngeal mucosa;
    immune system: allergic reactions, including anaphylaxis.

Special instructions and drug interactions

    when taken concurrently with other hypoglycemic drugs, as well as with insulin, it is recommended that their dosage be adjusted downward in order to reduce the risk of hypoglycemia;
    Before using Vipidia, in persons with kidney failure, it is necessary to evaluate their functions, and it is recommended to adjust the dosage of the drug in case of insufficiency of moderate severity;
The use of this drug in persons suffering from severe renal dysfunction is prohibited.
with a mild degree of impaired renal function, the daily dosage is 12.5 mg;
Alogliptin can cause the development of acute pancreatitis, and therefore, patients who are prescribed this medicine should be informed about the characteristic symptoms of pancreatitis. These include pulling pain in the abdomen, radiating to the back. When symptoms of acute pancreatitis appear, the medication is discontinued;
there is evidence of adverse effects of the drug on the liver, resulting in possible violation of its function. Therefore, before prescribing this drug, it is necessary to carefully examine and evaluate the functionality of the liver. If a violation is detected, it is recommended to cancel the funds;
Vipidia has no influence on the ability to manage transport or the speed of work that requires increased attention and concentration. However, in view of the possible development of hypoglycemia, caution is required;
precautions must be taken when prescribing to elderly people due to the possible presence of renal dysfunction, but in their absence, dose adjustment is not required;
in the study of interactions with other drugs, significant changes have been identified.

Terms and conditions of storage

Shelf life is 3 years. After the expiration of this period, the use of the drug is prohibited. The place to store the drug should be:
    out of reach of children;
    with a temperature not higher than 25 degrees.

Terms of sell

You can buy Vipidia without a prescription.